Eli Lilly recently spoke out against proposed tariffs on pharmaceuticals, warning they could increase drug costs and restrict patient access.  The drugmaker said it has invested more than $50 billion in U.S. manufacturing since 2020, including 10 projects aimed at supplying the domestic market entirely from within the country, according to an Aug. 14 news release from the company. 

President Donald Trump recently floated a tariff on pharmaceuticals as high as 250% as part of a greater push to bring more drug manufacturing to the U.S.  Eli Lilly also said although it supports efforts to make drug pricing more equitable globally, it calls for reforms that address systemic issues in the U.S. market — such as complex pricing structures, insurance cost sharings and misuse of programs including

See Full Page